All In Biotech

Drug Trial Radar · NCT03876717

Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea

Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Oct 25, 2018

Primary completion

Jul 1, 2021

Study completion Feb 13, 2022

Sponsor

Lead sponsor
Lars Kristian MunckAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pierre and Marie Curie University
First posted
Mar 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bile acid diarrhoea is a chronic disease that impairs quality of life. One in 100 has the condition and many suffer from the disease without knowing. The current test is called SeHCAT and is expensive and time-consuming and is unavailable in many places, including the US. The disease is often misdiagnosed as irritable bowel syndrome and estimated one third of patients with irritable bowel syndrome of the mixed type and the diarrhoea predominant type suffer from bile acid diarrhoea without knowing. A blood test called 7α-hydroxy-4-cholestene-3-one (C4) could make it much easier to diagnose bile acid diarrhoea. To establish the new test, the results of both C4 and SeHCAT are compared with the treatment effect of the drug called colesevelam. We invite patients who are referred for the SeHCAT test to participate in the trial. The SeHCAT test takes two days that are one week apart. The study patients register stool habits with a diary in the week between the SeHCAT visits. Based on the diary results, we screen for eligibility; e.g. a certain degree/severity of diarrhoea is required for participation. We treat eligible study patients (i.e those with diarrhoea) with either colesevelam or placebo (medicine without effect) that is randomly assigned. 170 study patients need to complete the treatment. We aim to validate (ie. compare) both the C4-test and the SeHCAT test with the colesevelam treatment response as the reference.

Conditions

  • Bile Acid Malabsorption
  • Chronic Diarrhea

Interventions

  • Colesevelam HydrochlorideDrug

    Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.

  • Placebo oral capsuleDrug

    Inactive placebo tablets over-encapsulated with DB caps AAA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intention-to-treat diarrhoea remission rate defined by the Hjortswang criteria for colesevelam in patients with BAD defined by C4 > 46 ng/mLTime frame: Intervention days 6 through 12 (last seven intervention days)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Hvidovre University Hospital

    Hvidovre, Denmark

  • Zealand University Hospital

    Køge, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.